Xin yixue (Apr 2023)

Effect of SGLT2 inhibitor on patients with STEMI complicated with type 2 diabetes mellitus after PCI

  • Du Shengli, Jia Zengqin, Zhang Qihua

DOI
https://doi.org/10.3969/j.issn.0253-9802.2023.04.010
Journal volume & issue
Vol. 54, no. 4
pp. 282 – 286

Abstract

Read online

Objective To evaluate the effect of sodium-glucose cotransporter-2 inhibitor （SGLT2i） on the efficacy and safety of percutaneous coronary intervention （PCI） in patients with acute ST segment elevation myocardial infarction （STEMI） complicated with type 2 diabetes mellitus. Methods Four hundred and six patients with STEMI complicated with type 2 diabetes mellitus undergoing PCI were selected and divided into the conventional treatment group and SGLT2i group according to whether SGLT2i was used. Clinical data were collected. Patients were followed up by outpatient or telephone. Results The incidence of MACE and heart failure readmission rate in the SGLT2i group were lower than those in the conventional treatment group （both P < 0.01）. After the adjustment of all risk factors， SGLT2i could reduce the incidence of MACE（OR=3.59，95%CI 9.43-1.36）and the risk of heart failure readmission（OR=4.54，95%CI 15.30-1.35）compared with conventional treatment. Conclusion SGLT2i is a safe treatment for STEMI patients complicated with type 2 diabetes mellitus after PCI， which can lower the incidence of MACE and heart failure readmission after surgery.

Keywords